{{Rsnum
|rsid=8062487
|Chromosome=16
|position=60439872
|Orientation=plus
|GMAF=0.3687
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(C;C)
|geno2=(C;T)
|geno3=(T;T)
}}{{ population diversity
| geno1=(C;C)
| geno2=(C;T)
| geno3=(T;T)
| CEU | 26.5 | 46.9 | 26.5
| HCB | 72.6 | 23.0 | 4.4
| JPT | 62.8 | 32.7 | 4.4
| YRI | 30.6 | 47.6 | 21.8
| ASW | 29.8 | 54.4 | 15.8
| CHB | 72.6 | 23.0 | 4.4
| CHD | 71.7 | 27.4 | 0.9
| GIH | 32.7 | 45.5 | 21.8
| LWK | 40.4 | 49.5 | 10.1
| MEX | 49.1 | 38.6 | 12.3
| MKK | 57.8 | 37.0 | 5.2
| TSI | 32.4 | 46.1 | 21.6
| HapMapRevision=28
}}{{PharmGKB
|RSID=rs8062487
|Name_s=
|Gene_s=-
|Feature=
|Evidence=PubMed ID:17537913
|Annotation=Risk or phenotype-associated allele: not stated Phenotype: Using a Quantitative Transmission Disequilibrium Test (QTDT), this variant was significantly associated with etoposide toxicity based upon IC50 values in cell lines from 30 parent-child trios. Study size: 87. Study population/ethnicity: 87 European descent Caucasians. Significance metric(s): p = 0.00001. Type of association: FA; GN.
|Drugs=etoposide
|Drug Classes=
|Diseases=Drug Toxicity
|Curation Level=Curated
|PharmGKB Accession ID=PA165109427
}}

{{GET Evidence
|impact=pharmacogenetic
|qualified_impact=Insufficiently evaluated pharmacogenetic
|inheritance=unknown
|quality_scores=Array
|dbsnp_id=rs8062487
|overall_frequency_n=77
|overall_frequency_d=126
|overall_frequency=0.611111
|n_genomes=42
|n_genomes_annotated=0
|n_haplomes=61
|n_articles=1
|n_articles_annotated=0
|in_pharmgkb=Y
|autoscore=1
|webscore=N
}}

{{on chip | 23andMe v1}}
{{on chip | 23andMe v2}}
{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | FTDNA2}}
{{on chip | FTDNA}}
{{on chip | HumanOmni1Quad}}
{{on chip | Illumina Human 1M}}